CN114008046A - 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 - Google Patents

作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 Download PDF

Info

Publication number
CN114008046A
CN114008046A CN202080046613.2A CN202080046613A CN114008046A CN 114008046 A CN114008046 A CN 114008046A CN 202080046613 A CN202080046613 A CN 202080046613A CN 114008046 A CN114008046 A CN 114008046A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
isomer
reaction
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080046613.2A
Other languages
English (en)
Other versions
CN114008046B (zh
Inventor
刘迎春
徐招兵
胡利红
丁照中
江文
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114008046A publication Critical patent/CN114008046A/zh
Application granted granted Critical
Publication of CN114008046B publication Critical patent/CN114008046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

一类作为CDK9抑制剂的氮杂吲哚连吡唑类化合物，具体涉及式(I)所示化合物、其药学上可接受的盐及其异构体，以及式(I)所示化合物、其药学上可接受的盐及其异构体以及包含它们的药用组合物在制备治疗癌症药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202080046613.2A 2019-06-27 2020-06-24 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 Active CN114008046B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910566823 2019-06-27
CN2019105668233 2019-06-27
PCT/CN2020/098002 WO2020259556A1 (zh) 2019-06-27 2020-06-24 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物

Publications (2)

Publication Number Publication Date
CN114008046A true CN114008046A (zh) 2022-02-01
CN114008046B CN114008046B (zh) 2023-08-18

Family

ID=74060028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046613.2A Active CN114008046B (zh) 2019-06-27 2020-06-24 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物

Country Status (3)

Country Link
US (1) US20220267321A1 (zh)
CN (1) CN114008046B (zh)
WO (1) WO2020259556A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022135580A1 (zh) * 2020-12-25 2022-06-30 南京明德新药研发有限公司 吡啶并吡咯类化合物的晶型、制备方法及其应用
CN113666934B (zh) * 2021-07-28 2023-06-23 北京深度制耀科技有限公司 Cdk9激酶抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149561A1 (en) * 2005-12-23 2007-06-28 Dashyant Dhanak Azaindole inhibitors of aurora kinases
US20170174703A1 (en) * 2014-03-24 2017-06-22 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as smo inhibitors
CN108884101A (zh) * 2016-03-25 2018-11-23 正大天晴药业集团股份有限公司 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
WO2019058132A1 (en) * 2017-09-22 2019-03-28 The University Of Nottingham HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF KINASE CDK12

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US20190263799A1 (en) * 2015-12-14 2019-08-29 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
CN108727363B (zh) * 2017-04-19 2020-06-19 劲方医药科技(上海)有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149561A1 (en) * 2005-12-23 2007-06-28 Dashyant Dhanak Azaindole inhibitors of aurora kinases
US20170174703A1 (en) * 2014-03-24 2017-06-22 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as smo inhibitors
CN108884101A (zh) * 2016-03-25 2018-11-23 正大天晴药业集团股份有限公司 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
WO2019058132A1 (en) * 2017-09-22 2019-03-28 The University Of Nottingham HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF KINASE CDK12

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEPHEN J. GREGSON ET AL.: "Pyrrolobenzodiazepine Dimer Antibody−Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers" *
赵祥麟;赵燕芳;徐德胜;黄丽荣;宫平;: "[1,2,4]三氮唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性" *

Also Published As

Publication number Publication date
CN114008046B (zh) 2023-08-18
US20220267321A1 (en) 2022-08-25
WO2020259556A1 (zh) 2020-12-30

Similar Documents

Publication Publication Date Title
CN112442030B (zh) 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
AU2018304757A1 (en) Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor
US11623923B2 (en) Uracil compound as c-MET/AXL inhibitor
EP3470409B1 (en) Benzotriazole-derived alpha and beta-unsaturated amide compound used as tgf-beta ri inhibitor
JP2022543767A (ja) 四環式化合物、その調製と使用の方法
US11319303B2 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
JP5728499B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
CN114555574A (zh) 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物
AU2020394767B2 (en) Spiro compound serving as ERK inhibitor, and application thereof
TW201823246A (zh) Cdk4/6抑制劑
WO2021228248A1 (zh) 氮杂稠环酰胺类化合物及其用途
CN114008046B (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
TW202128699A (zh) 治療性化合物
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
EP4061817A1 (en) Adenosine receptor antagonist compounds
CN114555600A (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
US20230095530A1 (en) Compound used as ret kinase inhibitor and application thereof
WO2023160572A1 (zh) 吡唑类衍生物、药物组合物及应用
CN112424189A (zh) 吡咯烷基脲衍生物及其在TrkA相关疾病的应用
CN113439080B (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
CN112752749A (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
WO2023143169A1 (zh) 含吲哚的大环类化合物及其应用
CN117658947A (zh) 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065753

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant